Immunocan

Immunocan

伊米诺康

Immunocan

Biotech/Healthcare

Founded in 2020, Shanghai Yiminokang Biotechnology Co., Ltd. is an early-stage biopharmaceutical company that applies gene-editing technology to build a platform for novel antibody therapeutics, supporting biomedical research and the development of new targeted drugs.

Latest round: Series A (2026)

Source: ChinaBulls — chinabulls.com

Last updated 2026-05-01

Funding history

Request access to view this section.

Investors

Request access to view this section.

HQ & website

Request access to view this section.

Tags

Request access to view this section.